Mesoblast Ltd
ASX:MSB
Mesoblast Ltd
Cash from Financing Activities
Mesoblast Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mesoblast Ltd
ASX:MSB
|
Cash from Financing Activities
$67.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Cash from Financing Activities
AU$76m
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
19%
|
|
CSL Ltd
ASX:CSL
|
Cash from Financing Activities
-$1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-8%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Financing Activities
-AU$2.7m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Financing Activities
AU$10.2m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Financing Activities
AU$28.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
22%
|
See Also
What is Mesoblast Ltd's Cash from Financing Activities?
Cash from Financing Activities
67.8m
USD
Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Cash from Financing Activities amounts to 67.8m USD.
What is Mesoblast Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-5%
Over the last year, the Cash from Financing Activities growth was 102%. The average annual Cash from Financing Activities growth rates for Mesoblast Ltd have been -11% over the past three years , -5% over the past five years .